Skip to main content

Table 1 FDA-approved ADCs for the treatment of solid tumors

From: Antibody–drug conjugates in solid tumors: a look into novel targets

 

Target

Payload

Linker

DAR

Indications

Trastuzumab emtansine

(T-DM1)

HER2

Maytansine

(microtubule inhibitor)

Non-cleavable thioether linker

3.5

HER2-positive mBC pretreated with trastuzumab and a taxane;

HER2-positive early BC with residual disease after neoadjuvant trastuzumab and taxanes

Trastuzumab deruxtecan

(T-DXd)

HER2

Deruxtecan (topoisomerase inhibitor)

Protease-cleavable linker

8

HER2-positive mBC progressing to two or more prior anti-HER2-based regimens in the metastatic setting

Enfortumab vedotin

(EV)

Nectin-4

Monomethyl auristatin E

(microtubule inhibitor)

Protease-cleavable linker

3.8

Locally advanced/metastatic UC previously treated with a PD-(L)1 and a platinum-based chemotherapy in the (neo)adjuvant or metastatic setting

Sacituzumab govitecan

(SG)

Trop-2

SN-38

(topoisomerase inhibitor)

Hydrolysable linker

7.5

Triple-negative mBC (who have received at least two prior therapies for metastatic disease)